Noble Financial analyst Ahu Demir maintained a Buy rating on Onconova Therapeutics (ONTX) on July 25. The company’s shares opened today at $2.60, close to its 52-week low of $1.69.
According to TipRanks.com, Demir is a 2-star analyst with an average return of 1.5% and a 29.4% success rate. Demir covers the Healthcare sector, focusing on stocks such as Dyadic International, Electrocore Llc, and TherapeuticsMD.
Onconova Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, representing a 534.6% upside. In a report issued on July 18, Maxim Group also maintained a Buy rating on the stock with a $8 price target.
See today’s analyst top recommended stocks >>
Based on Onconova Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.6 million. In comparison, last year the company had a GAAP net loss of $4.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.